

JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office: T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA) Fax: 0091-11-26498341, 26494708, Phone: 0091-11-26494519-24

CIN: L74899DL1978PLC009181

JPL/Stock-Corr-2013	February 14th, 2017				
The Manager	The Manager				
Listing Agreement	Listing Agreement				
The National Stock Exchange of India Ltd.	The Bombay Stock Exchange Ltd.				
Exchange Plaza,	Pherojbhoy Jeejeebhoy Tower				
Bandra-Kurla Complex	Dalal Street,				
Bandra (E), Mumbai - 400 051	Mumbai - 400 001.				
CM Quote : JAGSNPHARM	Scrip Code : 507789				
	NG OF BOARD OF DIRECTORS OF ICALS LIMITED HELD ON 14.02.2017				

Sir,

- Resignation form Dr. S. K. Goyal was received and accepted by Board of Directors.
- Performance of the 3rd Quarter and nine months ended 31.12.2016 (Un-audited) was placed before the Board having reviewed by the Audit Committee. The issue was discussed.
- Approval of 3rd Quarter and nine months performance ended 31.12.2016 was approved by the Board of Directors and resolution in this regard was passed with an authority to Managing Director to publish in newspapers and send same to National Stock Exchange of India Limited (NSE) & Bombay Stock Exchange Limited (BSE).
- Auditors Limited Review statement is enclosed.
- Other routine matters were discussed by Board and taken care.
- Any another matter with the permission. Meeting concluded with vote of thanks,
- The meeting commenced at 12.00 noon and concluded at 2.35 p.m.

Thanking you,

Yours faithfully,

For JAGSONPAL PHARMACEUTICALS I

R K KAPOOR 1

COMPLIANCE OFFICER & COMPANY SECRETARY



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office: T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA) Fax: 0091-11-26498341, 26494708, Phone: 0091-11-26494519-24

CIN No:- L74899DL1978PLC009181

Unaudited Financial Results for the Quarter / Half year ended 31.12.2016

Rs. in lacs

	Particulars	3 months ended 31.12.2016 Unaudited	3 months ended 30.09.2016 Unaudited	3 months ended 31.12.2015 Unaudited	9 Months ended 31.12.2016 Unaudited	9 Months ended 31.12.2015 Unaudited	12 Months Ended 31.03.2016 Audited
1	Income from operations		V			10.150.70	4 40 40 70
а	Net sales/Income from Operations (Net of excise duty)	3438.24	4001.90	3461.07	11451.16	10456.78	14348.79
b	Other Operating Income		14.02		27.17	30.94	59.26
-	Total Income from operations (net)	3438.24	4015.92	3461.07	11478.33	10487.72	14408.05
2	Expenses				55020000	5000 30	5007.00
а	Cost of materials consumed	1469.56	1212.16	1245.72	4355.62	4720.45	5627.89
b	Purchases of stock-in-trade	251.98	192.14	357.38	819.11	742.40	906.68
C.	Changes in inventories of finished goods,	-9.68	283.42	-338.86	-148.69	-979.13	-622.24
d.	Employee benefits expenses	967.87	1011.44	921.74	3095.42	2712.80	3783.71
e.	Depreciation and amortisation expense	33.29	72.80	74.22	176.52	216.44	309.36
f.	Other expenses	659.11	1094.02	1031.01	2789.29	2544.20	3471.80
	Total expenses	3372.13	3865.98	3291.21	11087.27	9957.16	13477.20
3	Profit from Operations before Other Income,						42545
-	Finance Cost and Exceptional items (1-2)	66.11	149.94	169.86	391.06	530.56	930.85
4	Other Income	0.03	0.06		0.12	6.31	6.38
5	Profit from ordinary activities before finance	66.14	150.00	169.86	391.18	536.87	937.23
	cost and Exceptional items (3+4)						
6	Finance Cost	59.12	87.07	121.22	241.06	365.23	529.71
7	Profit from ordinary activities after finance	7.02		48.64	150.12	171.64	407.52
	cost but before Exceptional Items (5-6)						
8	Exceptional Items	1279.81			1279.81		
9	Profit(+)/Loss(-) from Ordinary Activities	1286.83	62.93	48.64	1429.93	171.64	407.52
3	before tax (7+8)						
10	Tax expense	296.41	12.60	13.73	325.04	46.33	82.10
	Net Profit/Loss(-) from Ordinary Activities	990.42		34.91	1104.89	125.31	325.42
	after tax (9-10)						
12	Extraordinary Items (net of tax expense Rs.lacs	.)		2121	440400	405.04	325.42
13	Net Profit(+)/Loss(-) for the period(11-12)	990.42		34.91	1104.89	125.31	
14	Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90	1309.90	1309.90
15	Reserves excluding Revaluation reserves as						
	per Balance sheet of pr. Accounting yr						7742.63
16	Earnings Per Share (before extraordinary items	.)	Nuclearity	SAME AND A	granav	940.00	
a.		3.78		0.13	4.22	0.48	
b.	Diluted (Rs.)	3.78	0.19	0.13	4.22	0.48	1.24
Mot	96						

1) The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on February 14, 2017.

2) The Company operates in one reportable business segment i.e. 'Pharmaceuticals'.

3) Figures for the previous periods have been regrouped , wherever necessary, to correspond with the figures of the current period

4 Exception items include profit on sale of fixed assets at Pantnagar Plant as per the resolution passed by the shareholders at the resolution passed by the shareholders at the EGM held on April 12, 2016.

5) The above results are available on website of the company www.jagsonpal.com.

Place : New Delhi
Date : 14.2.2017

By Order of the Board

For Jagsonpal Pharmaceuticals Limite

Rajpal Singh Kochhar Managing Director DIN No 00059492

Factory: 20 K.M. Mathura Road. Post Office Amar Nagar, Faridabad-121003 (India) Phone: 0091-95129-2275952, 2275953 Factory: Plot No. 14, 15, 16, 55, 56, 57, Sector-5, IIE. Pant Nagar, Rudrapur (U.S. Nagar) - 263153 Uttara Khand

P.P. THUKRAL & CO.

CHARTERED ACCOUNTANTS

42, Ground Floor, World Trade Centre. Babar Road, New Delhi - 110 001

Ph. (O): 23413486

E-mail: sureshsethi62@yahoo.com

The Board of Director Jagsonpal Pharmaceuticals Limited T-210 J, Shahpur Jat New Delhi - 110049

SUBJECT: LIMITED REVIEW REPORT FOR JAGSONPAL PHARMACEUTICALS LIMITED

We have reviewed the unaudited financial results of Jagsonpal Pharmaceuticals Limited (the "Company") the Quarter ended 31.12.2016 which are included in the accompanying "Statement of Standalone Unaudited Financial Results for the Quarter ended 31st December, 2016" (the "statement"). The statement has been prepared by the Company pursuant to Regulation 33 of the SEBI, 2015 (Listing Obligations and Disclosure Requirements) Regulations 2015 (the Listing Regulations 2015) which has been initialed by us for identification purposes.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, engagements to Review of Interim Financial Information Performed by Independent Auditor of the entity" by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards specified under Section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) rule 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed including the manner in which it is to be disclosed, or that it contains any material misstatement.

> for P. P. THUKRAL & CO., **Chartered Accountants**

Place: New Delhi Date: 14.02.2017

PARTNER F.R. No. 000632N Membership No.89318